By skyforbes 
Long, J. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312–339 (2019).
Agirman, G., Yu, K. B. & Hsiao, E. Y. Signaling inflammation across the gut-brain axis. Science 374, 1087–1092 (2021).
Seo, D. O. & Holtzman, D. M. Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer’s disease. J. Gerontol. A Biol. Sci. Med. Sci. 75, 1232–1241 (2020).
Moore, A. M., Mathias, M. & Valeur, J. Contextualising the microbiota-gut-brain axis in history and culture. Micro. Ecol. Health Dis. 30, 1546267 (2019).
Bharti, R. & Grimm, D. G. Current challenges and best-practice protocols for microbiome analysis. Brief. Bioinform. 22, 178–193 (2021).
Cattaneo, A. et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging 49, 60–68 (2017).
Vogt, N. M. et al. Gut microbiome alterations in Alzheimer’s disease. Sci. Rep. 7, 13537 (2017).
Jemimah, S., Chabib, C. M. M., Hadjileontiadis, L. & AlShehhi, A. Gut microbiome dysbiosis in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis. PLoS ONE 18, e0285346 (2023).
Ferreiro, A. L. et al. Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease. Sci. Transl. Med. 15, eabo2984 (2023).
Zhuang, Z. Q. et al. Gut microbiota is altered in patients with Alzheimer’s disease. J. Alzheimers Dis. 63, 1337–1346 (2018).
Brandscheid, C. et al. Altered gut microbiome composition and tryptic activity of the 5xFAD Alzheimer’s mouse model. J. Alzheimers Dis. 56, 775–788 (2017).
Chen, C. et al. Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut 71, 2233-2252 (2022).
Sun, B. L. et al. Gut microbiota alteration and its time course in a tauopathy mouse model. J. Alzheimers Dis. 70, 399–412 (2019).
Ursell, L. K. et al. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J. Allergy Clin. Immunol. 129, 1204–1208 (2012).
Human, M. P. C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009).
Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. & Knight, R. Diversity, stability and resilience of the human gut microbiota. Nature 489, 220–230 (2012).
Fetzer, I. et al. The extent of functional redundancy changes as species’ roles shift in different environments. Proc. Natl Acad. Sci. USA 112, 14888–14893 (2015).
Harach, T. et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep. 7, 41802 (2017).
Dodiya, H. B. et al. Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes. J. Exp. Med. 216, 1542–1560 (2019).
Wang, X. L. et al. Helicobacter pylori filtrate impairs spatial learning and memory in rats and increases β-amyloid by enhancing expression of presenilin-2. Front. Aging Neurosci. 6, 66 (2014).
Kim, M. S. et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut 69, 283–294 (2020).
Seo, D. O. et al. ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science 379, eadd1236 (2023).
Koyuncu, O. O., Hogue, I. B. & Enquist, L. W. Virus infections in the nervous system. Cell Host Microbe 13, 379–393 (2013).
Itzhaki, R. F. et al. Microbes and Alzheimer’s disease. J. Alzheimers Dis. 51, 979–984 (2016).
Seaks, C. E. & Wilcock, D. M. Infectious hypothesis of Alzheimer disease. PLoS Pathog. 16, e1008596 (2020).
Readhead, B. et al. Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron 99, 64–82.e7 (2018).
Tzeng, N. S. et al. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 15, 417–429 (2018).
Senejani, A. G. et al. Borrelia burgdorferi Co-Localizing with Amyloid Markers in Alzheimer’s Disease Brain Tissues. J. Alzheimers Dis. 85, 889–903 (2022).
Chacko, A. et al. Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer’s disease risk. Sci. Rep. 12, 2759 (2022).
Dominy, S. S. et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 5, eaau3333 (2019).
Moir, R. D., Lathe, R. & Tanzi, R. E. The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement. 14, 1602–1614 (2018).
Eimer, W. A. et al. Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron 99, 56–63.e3 (2018).
Wu, Y. et al. Microglia and amyloid precursor protein coordinate control of transient Candida cerebritis with memory deficits. Nat. Commun. 10, 685 (2019).
Thapa, M. et al. Translocation of gut commensal bacteria to the brain. bioRxiv https://doi.org/10.1101/2023.08.30.555630 (2023).
Friedland, R. P. & Chapman, M. R. The role of microbial amyloid in neurodegeneration. PLoS Pathog. 13, e1006654 (2017).
Schäfer, K. H., Christmann, A. & Gries, M. Intra-gastrointestinal amyloid-β1–42 oligomers perturb enteric function and induce Alzheimer’s disease pathology. J. Physiol. 598, 4141–4142 (2020).
Jin, J. et al. Gut-derived β-amyloid: Likely a centerpiece of the gut-brain axis contributing to Alzheimer’s pathogenesis. Gut Microbes 15, 2167172 (2023).
Shi, Y. & Holtzman, D. M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18, 759–772 (2018).
Brandebura, A. N., Paumier, A., Onur, T. S. & Allen, N. J. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat. Rev. Neurosci. 24, 23–39 (2023).
Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18, 965–977 (2015).
Thion, M. S. et al. Microbiome influences prenatal and adult microglia in a sex-specific manner. Cell 172, 500–516.e16 (2018).
Hanamsagar, R. et al. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. Glia 66, 460 (2018).
Matcovitch-Natan, O. et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science 353, aad8670 (2016).
Spichak, S. et al. Microbially-derived short-chain fatty acids impact astrocyte gene expression in a sex-specific manner. Brain Behav. Immun. Health 16, 100318 (2021).
Erny, D. et al. Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease. Cell Metab. 33, 2260–2276.e7 (2021).
Mezö, C. et al. Different effects of constitutive and induced microbiota modulation on microglia in a mouse model of Alzheimer’s disease. Acta Neuropathol. Commun. 8, 119 (2020).
Dodiya, H. B. et al. Gut microbiota-driven brain Aβ amyloidosis in mice requires microglia. J. Exp. Med. 219, e20200895 (2022).
Hou, K. et al. Microbiota in health and diseases. Signal. Transduct. Target Ther. 7, 135 (2022).
Marizzoni, M. et al. A peripheral signature of Alzheimer’s disease featuring microbiota-gut-brain axis markers. Alzheimers Res. Ther. 15, 101 (2023).
Bettcher, B. M., Tansey, M. G., Dorothée, G. & Heneka, M. T. Peripheral and central immune system crosstalk in Alzheimer disease—a research prospectus. Nat. Rev. Neurol. 17, 689–701 (2021).
Minter, M. R. et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci. Rep. 6, 30028 (2016).
Köhler, C. A. et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand. 135, 373–387 (2017).
Bell, R. D. et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512–516 (2012).
Montagne, A. et al. APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β. Nat. Aging 1, 506–520 (2021).
Tang, Y., Chen, Y., Jiang, H. & Nie, D. Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death. Cell Death Differ. 18, 602–618 (2011).
den Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340 (2013).
Boland, B. et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J. Neurosci. 28, 6926–6937 (2008).
Bonfili, L. et al. Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci. Rep. 7, 2426 (2017).
Choi, H. & Mook-Jung, I. Functional effects of gut microbiota-derived metabolites in Alzheimer’s disease. Curr. Opin. Neurobiol. 81, 102730 (2023).
Dalile, B., Van Oudenhove, L., Vervliet, B. & Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478 (2019).
Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).
Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013).
Alves de Lima, K. et al. Meningeal γδ T cells regulate anxiety-like behavior via IL-17a signaling in neurons. Nat. Immunol. 21, 1421–1429 (2020).
van der Hee, B. & Wells, J. M. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol. 29, 700–712 (2021).
Sadler, R. et al. Short-chain fatty acids improve poststroke recovery via immunological mechanisms. J. Neurosci. 40, 1162–1173 (2020).
McMurran, C. E. et al. The microbiota regulates murine inflammatory responses to toxin-induced CNS demyelination but has minimal impact on remyelination. Proc. Natl Acad. Sci. USA 116, 25311–25321 (2019).
Abdel-Haq, R. et al. A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice. Elife 11, e81453 (2022).
Fernando, W. M. A. D. B. et al. Sodium butyrate reduces brain amyloid-β levels and improves cognitive memory performance in an Alzheimer’s disease transgenic mouse model at an early disease stage. J. Alzheimers Dis. 74, 91–99 (2020).
Jiang, Y., Li, K., Li, X., Xu, L. & Yang, Z. Sodium butyrate ameliorates the impairment of synaptic plasticity by inhibiting the neuroinflammation in 5XFAD mice. Chem. Biol. Interact. 341, 109452 (2021).
Cuervo-Zanatta, D. et al. Dietary fiber modulates the release of gut bacterial products preventing cognitive decline in an Alzheimer’s mouse model. Cell Mol. Neurobiol. 43, 1595–1618 (2023).
Killingsworth, J., Sawmiller, D. & Shytle, R. D. Propionate and Alzheimer’s disease. Front. Aging Neurosci. 12, 580001 (2020).
Baloni, P. et al. Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer’s disease. Cell Rep. Med. 1, 100138 (2020).
Connell, E. et al. Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia. Mol. Neurodegener. 17, 43 (2022).
Vogt, N. M. et al. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease. Alzheimers Res. Ther. 10, 124 (2018).
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210–215 (2018).
Parikh, I. J. et al. Murine gut microbiome association with APOE alleles. Front. Immunol. 11, 200 (2020).
Maldonado Weng, J. et al. Synergistic effects of APOE and sex on the gut microbiome of young EFAD transgenic mice. Mol. Neurodegener. 14, 47 (2019).
Tran, T. T. T. et al. APOE genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer’s disease pathophysiology. FASEB J. 33, 8221–8231 (2019).
Vitek, M. P., Brown, C. M. & Colton, C. A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30, 1350–1360 (2009).
Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626–638 (2016).
Colton, C. A., Brown, C. M. & Vitek, M. P. Sex steroids, APOE genotype and the innate immune system. Neurobiol. Aging 26, 363–372 (2005).
Hosang, L. et al. The lung microbiome regulates brain autoimmunity. Nature 603, 138–144 (2022).
Seo, D. O., Boros, B. D. & Holtzman, D. M. The microbiome: a target for Alzheimer disease. Cell Res. 29, 779–780 (2019).
Francino, M. P. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front. Microbiol. 6, 1543 (2015).
Rakuša, E., Fink, A., Tamgüney, G., Heneka, M. T. & Doblhammer, G. Sporadic use of antibiotics in older adults and the risk of dementia: a nested case-control study based on German Health Claims Data. J. Alzheimers Dis. 93, 1329–1339 (2023).
Hazan, S. Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. J. Int. Med. Res. 48, 300060520925930 (2020).
Park, S. H. et al. Cognitive function improvement after fecal microbiota transplantation in Alzheimer’s dementia patient: a case report. Curr. Med. Res. Opin. 37, 1739–1744 (2021).
Park, S. H. et al. Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection. Aging (Albany NY) 14, 6449–6466 (2022).
Akhgarjand, C., Vahabi, Z., Shab-Bidar, S., Etesam, F. & Djafarian, K. Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: a randomized, double-blind, and placebo-controlled study. Front. Aging Neurosci. 14, 1032494 (2022).
He, X. et al. The preventive effects of probiotic Akkermansia muciniphila on D-galactose/AlCl3 mediated Alzheimer’s disease-like rats. Exp. Gerontol. 170, 111959 (2022).
Zhu, G., Zhao, J., Wang, G. & Chen, W. Bifidobacterium breve HNXY26M4 attenuates cognitive deficits and neuroinflammation by regulating the gut–brain axis in APP/PS1 mice. J. Agric. Food Chem. 71, 4646–4655 (2023).
Bicknell, B. et al. Neurodegenerative and neurodevelopmental diseases and the gut-brain axis: the potential of therapeutic targeting of the microbiome. Int. J. Mol. Sci. 24, 9577 (2023).
Lancaster, S. M. et al. Global, distinctive, and personal changes in molecular and microbial profiles by specific fibers in humans. Cell Host Microbe 30, 848–862.e7 (2022).
Sonnenburg, J. L. & Bäckhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature 535, 56–64 (2016).
Wang, X. et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 29, 787–803 (2019).